Key result
Left atrial appendage occlusion showed similar cardiovascular mortality to antithrombotics but reduced non-procedural bleeding.
Why the study?
Landmark randomized controlled trials comparing left atrial appendage occlusion against direct oral anticoagulants are individually underpowered to detect small but clinically meaningful differences.
Does left atrial appendage occlusion reduce cardiovascular mortality, stroke, systemic embolism, or bleeding compared to direct oral anticoagulants or antiplatelets?
Meta-Analysis (n=5,890)
Yes
Does left atrial appendage occlusion reduce cardiovascular mortality, stroke, systemic embolism, or bleeding compared to direct oral anticoagulants or antiplatelets?
LAAO offers similar overall efficacy and safety to modern antithrombotics, providing a robust reduction in non-procedural bleeding at the potential cost of upfront procedural risk and a slight numerical increase in ischemic stroke.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I think the relatively wide noninferiority margins and the higher stroke finding – albeit with a lower bleeding risk – gave some people pause about the idea of doing LAAO in just about anyone with AFib. The standard indication though, thinking about this for people who've had some problems with anticoagulation, makes a lot of sense.”
“LAA occlusion and DOACs had similar risks of a composite CV outcome, but an increased risk of stroke with LAA occlusion seems likely.”
“It does make sense that in cases of very high risk of stroke, protection from an agent like a direct-acting oral anticoagulant likely would be superior to focal mechanical occlusion of the left atrial appendage. And it's also, I think, intuitive that the higher someone's bleeding risk [is], the more they would benefit from a bleeding-avoidance strategy.”
Supports LAAO for high-bleeding-risk AF patients; extends individual RCTs by confirming comparable stroke and mortality rates in pooled analysis.
BACKGROUND: Landmark randomized controlled trials (RCTs) comparing left atrial appendage occlusion (LAAO) against direct oral anticoagulants (DOACs) are individually underpowered for small but clinically meaningful differences. We performed a pooled meta-analysis to provide more precise efficacy and safety data. METHODS: Utilizing random-effects models, we pooled data from 5890 patients across four landmark RCTs (PRAGUE-17, CLOSURE-AF, OPTION, and CHAMPION-AF) at their longest follow-up. RESULTS: There were no significant differences between LAAO and antithrombotics in cardiovascular mortality (5.3% vs. 4.8%, p = 0.33), all-cause stroke (3.3% vs. 2.8%, p = 0.31), systemic embolism (0.2% vs. 0.1%, p = 0.68), or major bleeding (6.6% vs. 6.8%, p = 0.85). Non-procedural bleeding was significantly lower with LAAO (9.2% vs. 16.7%; RR 0.55; 95% CI 0.47-0.64; p < 0.0001), though there was a numerical trend toward more ischemic stroke events (2.7% vs. 2.0%; RR 1.35; 95% CI 0.97-1.88; p = 0.08). CONCLUSION: LAAO offers similar overall efficacy and safety to modern antithrombotics. It represents a clinical trade-off: accepting a known upfront procedural risk for a robust, long-term reduction in non-procedural bleeding, potentially at the cost of a slight numerical increase in ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Knijnik et al. (2026) reported a meta-analysis. Left atrial appendage occlusion (LAAO) vs. Direct oral anticoagulants (DOACs) or antiplatelets was evaluated on Cardiovascular mortality (p=0.33). Left atrial appendage occlusion showed similar cardiovascular mortality to antithrombotics but reduced non-procedural bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: